Charlie Marvalim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charlie Marvalim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Balram Chowbay
2 shared publications- Guillaume Thibault
School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
2 shared publications Jing Xiang Gimson Wong
2 shared publicationsNatalia Sutiman
2 shared publicationsAmit Jain
1 shared publication- Benjamin Si Han Ng
School of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore
1 shared publication
Latest Publications
- Open Access
Yeast FIT2 homolog is necessary to maintain cellular proteostasis by regulating lipid homeostasis
Lipid droplets (LDs) have long been regarded as inert cytoplasmic organelles with the primary function of housing excess intracellular lipids. More recently, LDs have been strongly implicated in conditions of lipid and protein dysregulation. The fat storage inducing transmembrane (FIT) family of proteins comprises of evolutionarily conserved endoplasmic reticulum (ER)-resident proteins that have been reported to induce LD formation. Here, we establish a model system to study the role of S. cerevisiae FIT homologues ( ScFIT ), SCS3 and YFT2 , in proteostasis and stress response pathways. While LD biogenesis and basal ER stress-induced unfolded protein response (UPR) remain unaltered in ScFIT mutants, SCS3 was found to be essential for proper stress-induced UPR activation and for viability in the absence of the sole yeast UPR transducer IRE1. Devoid of a functional UPR, scs3 mutants exhibited accumulation of triacylglycerol within the ER along with aberrant LD morphology, suggesting a UPR-dependent compensatory mechanism for LD maturation. Additionally, SCS3 was necessary to maintain phospholipid homeostasis. Strikingly, the absence of the ScFIT proteins results in the downregulation of the closely-related Heat Shock Response (HSR) pathway. In line with this observation, global protein ubiquitination and the turnover of both ER and cytoplasmic misfolded proteins is impaired in ScFIT cells, while a screen for interacting partners of Scs3 identifies components of the proteostatic machinery as putative targets. Taken together, these suggest that ScFIT proteins may modulate proteostasis and stress response pathways with lipid metabolism at the interface between the two cellular processes.
Open AccessYeast FIT2 homolog is necessary to maintain cellular proteostasis by regulating lipid homeostasis
Lipid droplets (LDs) have long been regarded as inert cytoplasmic organelles with the primary function of housing excess intracellular lipids. More recently, LDs have been strongly implicated in conditions of lipid and protein dysregulation. The fat storage inducing transmembrane (FIT) family of proteins comprises of evolutionarily conserved endoplasmic reticulum (ER)-resident proteins that have been reported to induce LD formation. Here, we establish a model system to study the role of S. cerevisiae FIT homologues ( ScFIT ), SCS3 and YFT2 , in proteostasis and stress response pathways. While LD biogenesis and basal ER stress-induced unfolded protein response (UPR) remain unaltered in ScFIT mutants, SCS3 was found to be essential for proper stress-induced UPR activation and for viability in the absence of the sole yeast UPR transducer IRE1. Devoid of a functional UPR, scs3 mutants exhibited accumulation of triacylglycerol within the ER along with aberrant LD morphology, suggesting a UPR-dependent compensatory mechanism for LD maturation. Additionally, SCS3 was necessary to maintain phospholipid homeostasis. Strikingly, the absence of the ScFIT proteins results in the downregulation of the closely-related Heat Shock Response (HSR) pathway. In line with this observation, global protein ubiquitination and the turnover of both ER and cytoplasmic misfolded proteins is impaired in ScFIT cells, while a screen for interacting partners of Scs3 identifies components of the proteostatic machinery as putative targets. Taken together, these suggest that ScFIT proteins may modulate proteostasis and stress response pathways with lipid metabolism at the interface between the two cellular processes.
- Top Cited PapersOpen Access
- 11 October 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (20) , 5055
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.
- 11 October 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (20) , 5055
Top Cited PapersOpen AccessExploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.
- Open Access
- 14 June 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8637
Membrane phospholipid alteration causes chronic ER stress through early degradation of homeostatic ER-resident proteins
Phospholipid homeostasis in biological membranes is essential to maintain functions of organelles such as the endoplasmic reticulum. Phospholipid perturbation has been associated to cellular stress responses. However, in most cases, the implication of membrane lipid changes to homeostatic cellular response has not been clearly defined. Previously, we reported that Saccharomyces cerevisiae adapts to lipid bilayer stress by upregulating several protein quality control pathways such as the endoplasmic reticulum-associated degradation (ERAD) pathway and the unfolded protein response (UPR). Surprisingly, we observed certain ER-resident transmembrane proteins, which form part of the UPR programme, to be destabilised under lipid bilayer stress. Among these, the protein translocon subunit Sbh1 was prematurely degraded by membrane stiffening at the ER. Moreover, our findings suggest that the Doa10 complex recognises free Sbh1 that becomes increasingly accessible during lipid bilayer stress, perhaps due to the change in ER membrane properties. Premature removal of key ER-resident transmembrane proteins might be an underlying cause of chronic ER stress as a result of lipid bilayer stress.
- 14 June 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 8637
Open AccessMembrane phospholipid alteration causes chronic ER stress through early degradation of homeostatic ER-resident proteins
Phospholipid homeostasis in biological membranes is essential to maintain functions of organelles such as the endoplasmic reticulum. Phospholipid perturbation has been associated to cellular stress responses. However, in most cases, the implication of membrane lipid changes to homeostatic cellular response has not been clearly defined. Previously, we reported that Saccharomyces cerevisiae adapts to lipid bilayer stress by upregulating several protein quality control pathways such as the endoplasmic reticulum-associated degradation (ERAD) pathway and the unfolded protein response (UPR). Surprisingly, we observed certain ER-resident transmembrane proteins, which form part of the UPR programme, to be destabilised under lipid bilayer stress. Among these, the protein translocon subunit Sbh1 was prematurely degraded by membrane stiffening at the ER. Moreover, our findings suggest that the Doa10 complex recognises free Sbh1 that becomes increasingly accessible during lipid bilayer stress, perhaps due to the change in ER membrane properties. Premature removal of key ER-resident transmembrane proteins might be an underlying cause of chronic ER stress as a result of lipid bilayer stress.
- 1 March 2017
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 27 (3) , 120-123
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients
The critical role of lysine demethylase 4A (KDM4A), in regulating chromatin structure and consequently in driving cellular proliferation and oncogenesis has been the focus of recent studies. Non-small-cell lung cancer (NSCLC) patients with adenocarcinoma histology who were homozygous for KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) were recently shown to have significantly worse overall survival (OS) compared with patients with the wild-type or the heterozygous genotype at this locus (hazard ratio=1.68, P=0.042). In the current study, we investigated the association between the same polymorphism with OS in our Asian NSCLC-adenocarcinoma patients comprising Chinese (N=572), Malays (N=50), and Indians (N=22). KDM4A SNP-A482 genotype status was determined by Sanger sequencing. OS was calculated from the date of diagnosis to date of death or censored at the date of last follow-up. Kaplan–Meier analysis, log-rank test, and Cox regression methods were utilized to evaluate OS outcomes. KDM4A SNP-A482 had a minor allele (C) frequency of 18.8% and a major allele (A) frequency of 81.2% in our Asian NSCLC (adenocarcinoma) patients. However, the OS in our Asian NSCLC patients homozygous for KDM4A SNP-A482 was not significantly different from those who were wild type or heterozygous at this locus [CC vs. AA/AC: median OS (95% confidence interval): 40.2 (18.7–61.6) vs. 29.6 (26.9–32.3) months; P=0.858]. The results remained statistically nonsignificant even after adjustment for epidermal growth factor receptor mutational status, suggesting that KDM4A SNP-A482 does not significantly influence OS in Asian NSCLC patients.
- 1 March 2017
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 27 (3) , 120-123
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients
The critical role of lysine demethylase 4A (KDM4A), in regulating chromatin structure and consequently in driving cellular proliferation and oncogenesis has been the focus of recent studies. Non-small-cell lung cancer (NSCLC) patients with adenocarcinoma histology who were homozygous for KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) were recently shown to have significantly worse overall survival (OS) compared with patients with the wild-type or the heterozygous genotype at this locus (hazard ratio=1.68, P=0.042). In the current study, we investigated the association between the same polymorphism with OS in our Asian NSCLC-adenocarcinoma patients comprising Chinese (N=572), Malays (N=50), and Indians (N=22). KDM4A SNP-A482 genotype status was determined by Sanger sequencing. OS was calculated from the date of diagnosis to date of death or censored at the date of last follow-up. Kaplan–Meier analysis, log-rank test, and Cox regression methods were utilized to evaluate OS outcomes. KDM4A SNP-A482 had a minor allele (C) frequency of 18.8% and a major allele (A) frequency of 81.2% in our Asian NSCLC (adenocarcinoma) patients. However, the OS in our Asian NSCLC patients homozygous for KDM4A SNP-A482 was not significantly different from those who were wild type or heterozygous at this locus [CC vs. AA/AC: median OS (95% confidence interval): 40.2 (18.7–61.6) vs. 29.6 (26.9–32.3) months; P=0.858]. The results remained statistically nonsignificant even after adjustment for epidermal growth factor receptor mutational status, suggesting that KDM4A SNP-A482 does not significantly influence OS in Asian NSCLC patients.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15722
Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on pancreatic ductal adenocarcinoma cell lines carrying different Kras mutational status.
E15722 Background: Gemcitabine plus erlotinib (G+E) is the standard of care for treatment of patients with pancreatic ductal adenocarcinoma (PDAC). The FOLFIRINOX regimen was shown to significantly improve the survival of PDAC patients over gemcitabine but occurred at the expense of significant toxicities, highlighting the crucial need for more effective treatment options that are tolerable. This study sought to investigate the effects of oxaliplatin, xeloda and irinotecan (OXIRI) regimen versus the G+E regimen in PDAC cell lines. Methods: The anti-proliferative effects of the drug combinations were analyzed in a panel of human PDAC cell lines, BxPC3 (KRASWT), PANC-1 (KRASG12D), MIAPaCa-2 (KRASG12C) and AsPC-1 (KRASG12D) (ATCC). Cells were treated at the following concentrations: oxaliplatin (0.0001 nM - 100 uM), SN-38 (0.00001 nM - 10 uM), 5-FU (0.0001 nM - 100 uM), gemcitabine (0.001 nM - 100 uM) and erlotinib (0.001 nM - 10 uM) and cell viability was assessed using the CCK-8 assay 72 hours after drug treatments. Cell cycle and apoptosis analyses were performed using FITC BrdU Flow Kit and Annexin V-FITC Assay, respectively, and results analyzed using FACSDiva v6.1.2. Results: As single agents, all four PDAC cells lines were most sensitive to oxaliplatin and least sensitive to erlotinib. The OXIRI regimen was more effective than gemcitabine alone, as well as the G+E regimen in inhibiting cell proliferation across all the four cell lines. At clinically relevant concentrations of oxaliplatin 10 uM, 5-FU 10 uM and SN-38 1 uM, greater than 90% growth inhibition was achieved in BxPC-3 and MIA PaCa-2 cells and greater than 80% inhibition was achieved in PANC-1 and AsPC-1 cells. In contrast, treatment with gemcitabine 100 uM and erlotinib 1-10 uM only resulted in approximately 50% growth inhibition in MIA PaCa-2, PANC-1 and AsPC-1 cells, and 67% growth inhibition in BxPC-3 cells. Notably, evidence of marked G2-M and S phase arrest and increased apoptosis were observed across all four cell lines treated with the OXIRI regimen. Conclusions: These findings suggest that the OXIRI regimen exhibits greater anti-cancer effects than the combination of gemcitabine and erlotinib in PDAC cell lines.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15722
Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on pancreatic ductal adenocarcinoma cell lines carrying different Kras mutational status.
E15722 Background: Gemcitabine plus erlotinib (G+E) is the standard of care for treatment of patients with pancreatic ductal adenocarcinoma (PDAC). The FOLFIRINOX regimen was shown to significantly improve the survival of PDAC patients over gemcitabine but occurred at the expense of significant toxicities, highlighting the crucial need for more effective treatment options that are tolerable. This study sought to investigate the effects of oxaliplatin, xeloda and irinotecan (OXIRI) regimen versus the G+E regimen in PDAC cell lines. Methods: The anti-proliferative effects of the drug combinations were analyzed in a panel of human PDAC cell lines, BxPC3 (KRASWT), PANC-1 (KRASG12D), MIAPaCa-2 (KRASG12C) and AsPC-1 (KRASG12D) (ATCC). Cells were treated at the following concentrations: oxaliplatin (0.0001 nM - 100 uM), SN-38 (0.00001 nM - 10 uM), 5-FU (0.0001 nM - 100 uM), gemcitabine (0.001 nM - 100 uM) and erlotinib (0.001 nM - 10 uM) and cell viability was assessed using the CCK-8 assay 72 hours after drug treatments. Cell cycle and apoptosis analyses were performed using FITC BrdU Flow Kit and Annexin V-FITC Assay, respectively, and results analyzed using FACSDiva v6.1.2. Results: As single agents, all four PDAC cells lines were most sensitive to oxaliplatin and least sensitive to erlotinib. The OXIRI regimen was more effective than gemcitabine alone, as well as the G+E regimen in inhibiting cell proliferation across all the four cell lines. At clinically relevant concentrations of oxaliplatin 10 uM, 5-FU 10 uM and SN-38 1 uM, greater than 90% growth inhibition was achieved in BxPC-3 and MIA PaCa-2 cells and greater than 80% inhibition was achieved in PANC-1 and AsPC-1 cells. In contrast, treatment with gemcitabine 100 uM and erlotinib 1-10 uM only resulted in approximately 50% growth inhibition in MIA PaCa-2, PANC-1 and AsPC-1 cells, and 67% growth inhibition in BxPC-3 cells. Notably, evidence of marked G2-M and S phase arrest and increased apoptosis were observed across all four cell lines treated with the OXIRI regimen. Conclusions: These findings suggest that the OXIRI regimen exhibits greater anti-cancer effects than the combination of gemcitabine and erlotinib in PDAC cell lines.